UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Recruiting · NCT06279026 · Registry updated 2024-02-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2024-02-26 | NCT06279026 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 13 |
| Second Affiliated Hospital of Soochow University | 48 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Second Affiliated Hospital of Soochow University | Suzhou | China | 8 |